Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Investors choosing between Bristol Myers Squibb (NYSE:BMY) and Vertex Pharmaceuticals (NASDAQ:VRTX) must decide between a steady value play and a high-growth innovator as they look toward 2027.

Bristol Myers Squibb operates as a diversified drug manufacturer with a vast global infrastructure and several blockbuster treatments. Vertex Pharmaceuticals acts as a focused biotechnology leader, using advanced science to create near-monopolies in specific disease niches. This comparison explores their financial health and risk profiles to determine which fits your investment strategy.

The case for Bristol Myers Squibb

Bristol Myers Squibb develops and delivers medicines for serious conditions, specifically in the fields of oncology, hematology, and neuroscience. The company sells its products mainly to wholesalers, distributors, and specialty pharmacies, while maintaining key alliances with partners like BioNTech (NASDAQ:BNTX) for global strategic collaborations. It also holds an agreement with the U.S. government to provide certain medications, such as Eliquis, to the Medicaid program.

In FY 2025, revenue reached around $48.2 billion, reflecting a slight decline of roughly 0.2% compared to the previous year. Despite this flat top-line growth, the company reported a net income of about $7.1 billion for the period. This represents a significant recovery from the prior year and resulted in a net margin, which measures how much profit is kept from every dollar of sales, of approximately 14.6%.

As of its December 2025 balance sheet, the company carries a debt-to-equity ratio of nearly 2.6x, indicating that its total liabilities are 2.6 times the value of its shareholder equity. Its current ratio, which measures the ability to pay short-term bills with short-term assets, is approximately 1.3x. For the fiscal year, free cash flow reached about $12.8 billion, which is the cash remaining after the company pays for its operating activities and capital expenditures.

The case for Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on transformative medicines for specialty markets, including cystic fibrosis and sickle cell disease. By targeting biotech stocks that dominate specific therapeutic areas, investors can often find companies with high pricing power. Vertex sells its treatments to major wholesalers and specialty distributors, and it works closely with CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) to develop new genetic therapies.

In FY 2025, revenue reached about $12.1 billion, representing an increase of approximately 9.6% over the prior year. This growth was accompanied by a net income of around $4.0 billion for the fiscal year. The company maintained a strong net margin of roughly 32.7%, showing that it retains a significant portion of its revenue as profit after all expenses are paid.

Based on its December 2025 balance sheet, the company shows a very conservative debt-to-equity ratio of roughly 0.2x. Its current ratio is approximately 2.9x, suggesting a high level of liquidity to meet its immediate financial obligations. Furthermore, the company generated free cash flow of around $3.2 billion, which helps fund its ongoing research and development into new treatment areas.

Risk profile comparison

Bristol Myers Squibb faces risks related to revenue concentration, as a large portion of its sales comes from a few key products, such as Eliquis and Opdivo. These medicines are susceptible to patent expirations and competition from generic alternatives, as well as legislative pricing controls. Additionally, the company manages a heavy regulatory burden and the constant possibility of high costs associated with late-stage drug trial failures or product liability claims.

Vertex Pharmaceuticals deals with its own concentration risks, as the majority of its revenue is tied to its cystic fibrosis franchise. The company is under constant pressure to successfully launch next-generation medications to maintain its market position. Furthermore, the high operational complexity of manufacturing genetic therapies like Casgevy, along with potential intellectual property litigation involving Editas Medicine (NASDAQ:EDIT), creates ongoing uncertainty for the business.

Valuation comparison

Bristol Myers Squibb appears much cheaper based on its earnings multiples, while Vertex Pharmaceuticals carries a higher price tag that reflects its superior growth and profit margins.

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy for 2027?

Vertex Pharmaceuticals continues to benefit from its focus on cystic fibrosis (CF). It recently launched Alyftrek, a once-daily, next-in-class, triple-combination CF regimen. The treatment is seen encouragingly by investors. Alyftrek marks a notable improvement to the twice-daily dosage of Vertex's other CF products and was approved in Australia, New Zealand, Switzerland, the European Union, the U.K., and Canada over the course of 2025, after the U.S. approved it in 2024. Plenty more jurisdictions are evaluating the treatment today. In the U.S., label extensions (the expansion of FDA approval for use) mean Vertex can treat 95% of people with cystic fibrosis in the country today.

Vertex has expanded into treating other conditions. Povetacicept, an investigational recombinant fusion protein therapeutic, continues to show best-in-class potential as a treatment for three chronic autoimmune diseases: IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and generalized myasthenia gravis (gMG). The FDA has granted its Breakthrough Therapy Designation for IgAN, with potential approval by Nov. 30 this year, as well as Fast Track Designation for pMN. If approved across the IgAN, pMN, and gMG indications, peak annual sales could reach $4 billion to $7 billion, according to equity analyst firm Argus.

For fiscal 2026, Vertex sales should rise about 10% to $13.3 billion, with net income coming in roughly even with 2025.

Bristol Myers Squibb, meanwhile, has made positive strides, with its newer growth brands gaining traction and some interesting candidates in the pipeline. The stock is cheap, and that seems to be for good reason. Investors have already priced in much of the upcoming difficulty, which softens the downside but does not make it an obvious buy right now. Bristol Myers Squibb's recovery timeline is hard to predict.

Revenue for the current fiscal year should edge up 3% to $49.8 billion, with a much healthier rise in net income of more than 40% to $11.2 billion.

Bristol Myers has attractively low forward price-to-earnings and price-to-sales ratios, but, of course, that reflects some continued rough sailing ahead. Vertex isn't cheap, but sometimes the better stocks are the ones that have convinced the market their growth prospects are very strong, as Vertex's seem to be. In this case, go with the pharma company firing on all cylinders; go with Vertex.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Bristol Myers Squibb, Moderna, and Vertex Pharmaceuticals. The Motley Fool recommends Editas Medicine. The Motley Fool has a disclosure policy.